Ok, here is my best *guess*.
Copper is weaker than I would want right now but we have reports of strong USA economy. A strong USA economy means China is doing better than they say it is because all we buy in the USA is Chinakrap.
Copper is $2.90. I would rather see it about $3. I think it needs to be over $3 for TC to trade over $2 by Jan 16 2015.
Gold is doing better than I thought since I secretly though there might be something to Goldman's $1050 prediction (not that they are prognosticators but rather they have an effect on markets with their opinions).
Sill, Gold is $1177. I think it needs to be over $1200 for TC to trade over $2 by Jan 16 2015.
I expect TC to trade in the range of $1.50 to $1.90 leading up to Jan 16. Most likely right after my options expire it will go to $2.30 on some news.
So there is my call. $1.50 to $1.90 by Jan 16 unless copper is above $3 and gold is above $1200.
Maybe. I see things like this go crazy low then shoot back up to crazy high. Gilead went to $64 this summer, then traded for $117.
More earnings than the GDP of a small country in one quarter.
Imagine if everything came under cost control of providers.
What a world.
Imagine if you will, two identical patients with Hep C. One has to take 6 pills a day with side effects. The other has only to take one pill. Feel cheated?
Fill the sleigh boys!
They say the sole provider of Hep C treatment is Abbvie cocktail.
I wasn't being negative on ECYT as I own 4000 shares. I mean it could be a reason ECYT was down today on low volume. All of the bios are selling off today based on the ABBV pricing issue.
Cancer treatments go for $200,000 a patient in some cases. If you give pricing control to the providers, then they may ban a certain treatment if it is too costly.
No, they have no other drugs. I think at one time they thought about doing something to try and help AIDS patients but it never went anywhere.
Only down about 1.5%.
I wonder now at some of the chemo drugs that are $200,000 per treatment. Can Express Scripts pick just one and say that one is good enough for everyone?
No, the reason this is dropping is ABBV just pooped on Gilead and the rest of the biotech sector by handing pricing control to the insurance providers.